|Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components.|
|PMID: 18209487 Owner: NLM Status: MEDLINE|
|BACKGROUND/AIMS: Chronic inhibition of nitric oxide (NO) synthesis is associated with hypertension, myocardial ischemia, oxidative stress and hypertrophy; expression of adrenomedullin (AM) and intermedin (IMD) and their receptor activity modifying proteins (RAMPs 1-3) is augmented in cardiomyocytes, indicating that the myocardial AM/ IMD system may be activated in response to pressure loading and ischemic insult. The aim was to examine effects on (i) parameters of cardiomyocyte hypertrophy and on (ii) expression of AM and IMD and their receptor components in NO-deficient cardiomyocytes of an intervention chosen specifically for ability to alleviate pressure loading and ischemic injury concurrently.
METHODS: The NO synthesis inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME, 35 mg.kg(-1).day(-1)) was given to rats for 8 weeks, with/ without concurrent administration of beta-adrenoceptor antagonist, atenolol (25 mg.kg(-1).day(-1)) / calcium channel blocker, nifedipine (20mg.kg(-1).day(-1)).
RESULTS: In L-NAME treated rats, atenolol / nifedipine abolished increases in systolic blood pressure and plasma AM and IMD levels and in left ventricular cardiomyocytes: (i) normalized increased cell width and mRNA expression of hypertrophic (sk-alpha-actin) and cardio-endocrine (ANP, BNP, ET) genes; (ii) normalized augmented membrane protein oxidation; (iii) normalized mRNA expression of AM, IMD, RAMP1, RAMP2 and RAMP3.
CONCLUSIONS: normalization of blood pressure and membrane oxidant status together with prevention of hypertrophy and normalization of the augmented expression of AM, IMD and their receptor components in NO-deficient cardiomyocytes by atenolol / nifedipine supports involvement of both pressure loading and ischemic insult in stimulating cardiomyocyte hypertrophy and induction of these counter-regulatory peptides and their receptor components. Attenuation of augmented expression of IMD in this model cannot however be explained simply by prevention of cardiomyocyte hypertrophy.
|David Bell; You You Zhao; Adrian B Devine; Barbara J McDermott|
Related Documents :
|3101477 - A comparative evaluation of hemodynamic and neurohumoral effects of nitroglycerin and n...
2530977 - Genetic and non-genetic control of myocardial calcium.
25221717 - The magnitude of obesity and its relationship to blood pressure among the residents of ...
2372167 - Supraventricular tachyarrhythmias and rate-related hypotension: cardiovascular effects ...
16866117 - Use of negative-pressure dressings to manage a difficult surgical neck wound.
10608477 - A comparison of enalapril 20 mg once daily versus 10 mg twice daily in terms of blood p...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-01-17|
|Title: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology Volume: 21 ISSN: 1015-8987 ISO Abbreviation: Cell. Physiol. Biochem. Publication Date: 2008|
|Created Date: 2008-01-22 Completed Date: 2008-03-26 Revised Date: 2010-12-01|
Medline Journal Info:
|Nlm Unique ID: 9113221 Medline TA: Cell Physiol Biochem Country: Switzerland|
|Languages: eng Pagination: 203-14 Citation Subset: IM|
|Cardiovascular Research Group, Division of Medicine and Therapeutics, School of Medicine and Dentistry, The Queen's University of Belfast, Belfast, Northern Ireland, UK. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Atenolol / pharmacology*
Atrial Natriuretic Factor / genetics, metabolism
Blood Pressure / drug effects
Endothelin-1 / genetics, metabolism
Gene Expression Regulation / drug effects
Intracellular Signaling Peptides and Proteins / genetics, metabolism
Membrane Proteins / genetics, metabolism
Myocytes, Cardiac / drug effects*, metabolism, pathology*
NG-Nitroarginine Methyl Ester / administration & dosage, pharmacology
Natriuretic Peptide, Brain / genetics, metabolism
Neuropeptides / blood, genetics, metabolism*
Nifedipine / pharmacology*
Nitric Oxide / deficiency*
Oxidative Stress / drug effects
Peptides / genetics, metabolism
Protein Precursors / genetics, metabolism
Receptor Activity-Modifying Protein 1
Receptor Activity-Modifying Protein 3
Receptor Activity-Modifying Proteins
Receptors, Cell Surface / genetics, metabolism*
Systole / drug effects
|0/Endothelin-1; 0/Intracellular Signaling Peptides and Proteins; 0/Membrane Proteins; 0/Neuropeptides; 0/Peptides; 0/Protein Precursors; 0/Ramp1 protein, rat; 0/Ramp2 protein, rat; 0/Ramp3 protein, rat; 0/Receptor Activity-Modifying Protein 1; 0/Receptor Activity-Modifying Protein 3; 0/Receptor Activity-Modifying Proteins; 0/Receptors, Cell Surface; 0/intermedin protein, rat; 10102-43-9/Nitric Oxide; 114471-18-0/Natriuretic Peptide, Brain; 148498-78-6/Adrenomedullin; 21829-25-4/Nifedipine; 29122-68-7/Atenolol; 50903-99-6/NG-Nitroarginine Methyl Ester; 85637-73-6/Atrial Natriuretic Factor|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Retinoic acid induced suicidal erythrocyte death.
Next Document: Induction of IFN-gamma gene expression by thioredoxin: positive feed-back regulation of Th1 response...